311 related articles for article (PubMed ID: 34484468)
81. Characteristics of the immunogenicity and tumor immune microenvironment in
Wang Q; Mao Z; Li W; Wang S; Wang L; Chen L; Yang Z; Fu X; Jiang P; Bai Y; Xu L; Zhang S; Hou Y; Jia X; Jiang L; Liu M; Zhang G; Jiang Y; Guo H
Front Immunol; 2022; 13():1042072. PubMed ID: 36591290
[TBL] [Abstract][Full Text] [Related]
82. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
83. Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma.
Koike C; Okudela K; Matsumura M; Mitsui H; Suzuki T; Arai H; Kataoka T; Ishikawa Y; Umeda S; Tateishi Y; Ohashi K
Histol Histopathol; 2021 Mar; 36(3):305-315. PubMed ID: 33368138
[TBL] [Abstract][Full Text] [Related]
84. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
[TBL] [Abstract][Full Text] [Related]
85. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
86. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
87. Tumor inflammatory microenvironment contribution to survival in resected upstaged adenocarcinomas.
Bonis A; Verzeletti V; Lunardi F; Lione L; Cannone G; Faccioli E; Mammana M; Nicotra S; Calabrese F; Dell'Amore A; Rea F
Eur J Surg Oncol; 2024 Jul; 50(7):108444. PubMed ID: 38824816
[TBL] [Abstract][Full Text] [Related]
88. Aberrant Expression of β-Catenin Correlates with Infiltrating Immune Cells and Prognosis in NSCLC.
Zheng H; Ning Y; Yang Y; Zhan Y; Wang H; Wen Q; Peng J; Fan S
Pathol Oncol Res; 2021; 27():1609981. PubMed ID: 34764821
[No Abstract] [Full Text] [Related]
89. Landscape and dynamics of single tumor and immune cells in early and advanced-stage lung adenocarcinoma.
Chen Z; Huang Y; Hu Z; Zhao M; Li M; Bi G; Zheng Y; Liang J; Lu T; Jiang W; Xu S; Zhan C; Xi J; Wang Q; Tan L
Clin Transl Med; 2021 Mar; 11(3):e350. PubMed ID: 33783985
[TBL] [Abstract][Full Text] [Related]
90. Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.
Yi M; Li A; Zhou L; Chu Q; Luo S; Wu K
Cancer Immunol Immunother; 2021 Jun; 70(6):1705-1719. PubMed ID: 33386920
[TBL] [Abstract][Full Text] [Related]
91. Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.
Ohba T; Toyokawa G; Kometani T; Nosaki K; Hirai F; Yamaguchi M; Hamatake M; Seto T; Ichinose Y; Sugio K
Surg Today; 2014 Mar; 44(3):478-86. PubMed ID: 23609009
[TBL] [Abstract][Full Text] [Related]
92. Clinicopathologic characteristics and EGFR mutations in lung cancer patients aged below 45 years.
Xia J; Li H; Ji Y; Mi C; Chen G; Li P; Zhang R; Chen W; Wang J
Curr Probl Cancer; 2019 Aug; 43(4):363-370. PubMed ID: 30522775
[TBL] [Abstract][Full Text] [Related]
93. High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.
Mori S; Motoi N; Ninomiya H; Matsuura Y; Nakao M; Mun M; Okumura S; Nishio M; Morikawa T; Ishikawa Y
Pathol Int; 2017 Jan; 67(1):37-44. PubMed ID: 27976463
[TBL] [Abstract][Full Text] [Related]
94. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
95. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
96. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
Wang Z; Chen X
Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
[TBL] [Abstract][Full Text] [Related]
97. Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma.
Bischoff P; Trinks A; Obermayer B; Pett JP; Wiederspahn J; Uhlitz F; Liang X; Lehmann A; Jurmeister P; Elsner A; Dziodzio T; Rückert JC; Neudecker J; Falk C; Beule D; Sers C; Morkel M; Horst D; Blüthgen N; Klauschen F
Oncogene; 2021 Dec; 40(50):6748-6758. PubMed ID: 34663877
[TBL] [Abstract][Full Text] [Related]
98. PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma.
Isobe K; Kakimoto A; Mikami T; Kaburaki K; Kobayashi H; Yoshizawa T; Nakano Y; Makino T; Otsuka H; Sano G; Sugino K; Sakamoto S; Takai Y; Tochigi N; Iyoda A; Homma S
Oncol Rep; 2018 Jul; 40(1):331-338. PubMed ID: 29767258
[TBL] [Abstract][Full Text] [Related]
99. PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.
Takada K; Toyokawa G; Tagawa T; Kohashi K; Shimokawa M; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y
Lung Cancer; 2018 Feb; 116():1-6. PubMed ID: 29413045
[TBL] [Abstract][Full Text] [Related]
100. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]